Navigation Links
Effective treatment for sickle cell underused by doctors
Date:6/17/2008

Uncertainties about proper use and possible long-term effects of hydroxyurea in the treatment of sickle cell anemia may be wrongly influencing doctors to avoid prescribing it to those in serious need, according to results of a literature review by specialists at Johns Hopkins.

"We know that many people with sickle cell disease aren't being offered this drug, which is the only one we have to treat this disease," says Sophie Lanzkron, M.D., assistant professor of medicine and oncology at the Johns Hopkins University School of Medicine and director of the Sickle Cell Center for Adults at Johns Hopkins.

In a bid to heighten awareness about the nature of the uncertainties and correct clinical use of the drug, the U.S. Department of Health and Human Services selected Lanzkron and her colleagues at Johns Hopkins to gather information from previously published studies on hydroxyurea.

First, they combed through databases to select randomized clinical trials, observational studies and case reports that evaluated the drug's effectiveness and incidences of toxic side effects. They excluded the poorer quality data and non-English publications and carefully analyzed data from 246 articles.

What emerged, the researchers say, is a clear picture of the drug's effectiveness.

Specifically, they found that the number of intensely painful sickle cell "crises," caused when misshapen, "sickled" red blood cells clump in blood vessels, dropped by 68 to 84 percent in people taking hydroxyurea. Their hospital admissions declined by 18 to 32 percent.

On the biological side, amounts of fetal hemoglobin, a blood component that seems to decrease sickle cell symptoms, increased by 4 to 20 percent after patients began taking hydroxyurea.

On the negative side of the risk/benefit ledger, studies in mice also indicated that hydroxyurea impairs sperm development. The researchers concluded that this effect could be present in human patients as well. The review could not conclude with any confidence that hydroxyurea increased or decreased the risk of leukemia or other tumors, leg ulcers and pregnancy complications.

In the team's report, published in the June 17 Annals of Internal Medicine, they conclude that hydroxyurea be considered a viable treatment option, but emphasized the need for more quality research.

"It's clear from our literature review that hydroxyurea works, but we need to do much more work to understand how it works and the best ways to use it," Lanzkron says.

Sickle cell anemia, an inherited disorder that affects mostly people of African and Hispanic heritage, is named for the crescent- or sickle-shaped blood cells caused by the disease. The C-shaped cells periodically clump inside blood vessels, blocking circulation and causing severe anemia, increased risk of infections or strokes, and episodes of extreme pain that can last hours or days. About 70,000 people have sickle cell disease in the United States.


'/>"/>

Contact: Christen Brownlee
cbrownlee@jhmi.edu
410-955-7832
Johns Hopkins Medical Institutions
Source:Eurekalert

Related medicine news :

1. Effective Communication of Clinical Studies for Maximum Impact
2. Winning Method - Effective Identification and Development of Clinical Investigators
3. Adalimumab therapy effective in AS, RA and PsA patients refractory to other anti-TNF therapies
4. Hand bone mineral density is an effective predictor of mortality in rheumatoid arthritis
5. Whole Milk Cheaper, Effective Contrast Agent for GI Scans
6. Tracking Cancer Drugs Effectiveness
7. ECRI Institutes Alert and Recall Management System Expands Effectiveness with New Content and Filters
8. Exposure Therapy Effective in Preventing Post-Traumatic Stress
9. Study of anti-CD20 therapy effective B cell depletion
10. Whole milk is effective and cost-effective as oral contrast agent
11. £1.2M trial to test effectiveness of cognitive behavioral therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2017)... ... September 21, 2017 , ... The American ... Health Services for professionals in the addiction treatment industry entitled: Special Investigations ... , Insurance companies and state and federal governments are increasingly scrutinizing the addiction ...
(Date:9/21/2017)... ... September 21, 2017 , ... ... communities, nine governmental public health departments have been awarded five-year accreditation status through ... that the benefits of being served by a PHAB-accredited health department now ...
(Date:9/21/2017)... ... September 21, 2017 , ... Innovatum will demonstrate capabilities of ... Healthcare Conference 2017 in Chicago, IL on October 17-19, 2017. This unique development ... improving patient safety. , Microscan , a global technology leader in ...
(Date:9/21/2017)... ... September 21, 2017 , ... Japanese Zen artist couple, Fumie and Kentaro Mune, ... and 8th October at Miranda Kuo Gallery on Lower East Side, NYC. This exhibition ... Kodo mat. Wanderlust , one of the largest US yoga online media outlets ...
(Date:9/21/2017)... ... September 21, 2017 , ... Sagora Senior Living, ... Isle at Kingwood Assisted Living and Memory Care located at 24025 Kingwood Place ... 55 assisted living apartments, 43 memory care apartments and 23 extended care apartments. ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... 2017   BioLife Solutions , Inc. (NASDAQ: ... clinical grade cell and tissue hypothermic storage and ... Rice , President and CEO, will be presenting at two ... & Renshaw 19 th Annual Global Investment Conference on ... Pacific time). The conference is being held at the New ...
(Date:9/6/2017)... , Sept. 6, 2017  Medical professionals ... and skills while treating their patients. Medical ... experience without involving patients. Simulation provides a ... can carry out procedures, refine techniques and ... Integration of new technology, such as augmented ...
(Date:9/6/2017)... NeuroRx, a clinical stage biopharma company developing the first oral ... granted Fast Track status by the US Food and Drug ... by NRX-101 (D-cycloserine + lurasidone). The company will shortly begin ... targeting patients who are admitted to Emergency Departments with ASIB ... ...
Breaking Medicine Technology: